MRKR Stock Overview
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications in the United States.
+ 1 more risk
Marker Therapeutics Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$0.34|
|52 Week High||US$3.20|
|52 Week Low||US$0.25|
|1 Month Change||13.33%|
|3 Month Change||-31.73%|
|1 Year Change||-89.00%|
|3 Year Change||-95.79%|
|5 Year Change||-90.98%|
|Change since IPO||-100.00%|
Recent News & Updates
Companies Like Marker Therapeutics (NASDAQ:MRKR) Could Be Quite Risky
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Marker Therapeutics (NASDAQ:MRKR) Will Have To Spend Its Cash Wisely
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
|MRKR||US Biotechs||US Market|
Return vs Industry: MRKR underperformed the US Biotechs industry which returned -24.3% over the past year.
Return vs Market: MRKR underperformed the US Market which returned -18.4% over the past year.
|MRKR Average Weekly Movement||11.7%|
|Biotechs Industry Average Movement||13.2%|
|Market Average Movement||8.1%|
|10% most volatile stocks in US Market||16.6%|
|10% least volatile stocks in US Market||3.2%|
Stable Share Price: MRKR is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 12% a week.
Volatility Over Time: MRKR's weekly volatility (12%) has been stable over the past year.
About the Company
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells expressing tumor-associated antigens. The company’s MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma, and various solid tumors; allogeneic T cells for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia; and off-the-shelf products in various indications.
Marker Therapeutics Fundamentals Summary
|MRKR fundamental statistics|
Is MRKR overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|MRKR income statement (TTM)|
|Cost of Revenue||US$29.18m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.52|
|Net Profit Margin||-1,949.65%|
How did MRKR perform over the long term?See historical performance and comparison
Is MRKR undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 2/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for MRKR?
Other financial metrics that can be useful for relative valuation.
|What is MRKR's n/a Ratio?|
Price to Sales Ratio vs Peers
How does MRKR's PS Ratio compare to its peers?
|MRKR PS Ratio vs Peers|
|Company||PS||Estimated Growth||Market Cap|
PHAS PhaseBio Pharmaceuticals
SBFM Sunshine Biopharma
CASI CASI Pharmaceuticals
MRKR Marker Therapeutics
Price-To-Sales vs Peers: MRKR is good value based on its Price-To-Sales Ratio (12.8x) compared to the peer average (17.9x).
Price to Earnings Ratio vs Industry
How does MRKR's PE Ratio compare vs other companies in the US Biotechs Industry?
Price-To-Sales vs Industry: MRKR is good value based on its Price-To-Sales Ratio (12.8x) compared to the US Biotechs industry average (14.1x)
Price to Sales Ratio vs Fair Ratio
What is MRKR's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||12.8x|
|Fair PS Ratio||0.00001x|
Price-To-Sales vs Fair Ratio: MRKR is expensive based on its Price-To-Sales Ratio (12.8x) compared to the estimated Fair Price-To-Sales Ratio (0x).
Share Price vs Fair Value
What is the Fair Price of MRKR when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate MRKR's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate MRKR's fair value for valuation analysis.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate MRKR's PEG Ratio to determine if it is good value.
Discover undervalued companies
How is Marker Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Future Growth Score2/6
Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MRKR is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: MRKR is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: MRKR is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: MRKR's revenue (52.4% per year) is forecast to grow faster than the US market (8.4% per year).
High Growth Revenue: MRKR's revenue (52.4% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if MRKR's Return on Equity is forecast to be high in 3 years time
Discover growth companies
How has Marker Therapeutics performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: MRKR is currently unprofitable.
Growing Profit Margin: MRKR is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: MRKR is unprofitable, and losses have increased over the past 5 years at a rate of 6.8% per year.
Accelerating Growth: Unable to compare MRKR's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MRKR is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).
Return on Equity
High ROE: MRKR has a negative Return on Equity (-120.46%), as it is currently unprofitable.
Discover strong past performing companies
How is Marker Therapeutics's financial position?
Financial Health Score4/6
Financial Health Score 4/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: MRKR's short term assets ($31.0M) exceed its short term liabilities ($8.2M).
Long Term Liabilities: MRKR's short term assets ($31.0M) exceed its long term liabilities ($11.0M).
Debt to Equity History and Analysis
Debt Level: MRKR is debt free.
Reducing Debt: MRKR has no debt compared to 5 years ago when its debt to equity ratio was 0.1%.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: MRKR has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: MRKR has less than a year of cash runway if free cash flow continues to reduce at historical rates of 32.2% each year
Discover healthy companies
What is Marker Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate MRKR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate MRKR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if MRKR's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if MRKR's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as MRKR has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Peter Hoang (49 yo)
Mr. Peter L. Hoang, MBA, has been the President and Chief Executive Officer of Marker Therapeutics, Inc. (formerly known as TapImmune, Inc.) since September 22, 2017. Mr. Hoang has over 18 years of finance...
CEO Compensation Analysis
Compensation vs Market: Peter's total compensation ($USD1.62M) is above average for companies of similar size in the US market ($USD748.70K).
Compensation vs Earnings: Peter's compensation has increased whilst the company is unprofitable.
Experienced Management: MRKR's management team is considered experienced (3.3 years average tenure).
Experienced Board: MRKR's board of directors are considered experienced (4.1 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Marker Therapeutics, Inc.'s employee growth, exchange listings and data sources
- Name: Marker Therapeutics, Inc.
- Ticker: MRKR
- Exchange: NasdaqGM
- Founded: 1999
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$28.247m
- Shares outstanding: 83.08m
- Website: https://www.markertherapeutics.com
Number of Employees
- Marker Therapeutics, Inc.
- 3200 Southwest Freeway
- Suite 2500
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/06/27 00:00|
|End of Day Share Price||2022/06/27 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.